Cefmenoxime: A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.Cefotaxime: Semisynthetic broad-spectrum cephalosporin.Cefotiam: One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.Proteus vulgaris: A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in soil, fecal matter, and sewage. It is an opportunistic pathogen and causes cystitis and pyelonephritis.Hydroxybenzoate Ethers: Benzoate derivatives that contain one or more alkyl or aryl groups linked to the benzene ring structure by OXYGEN.Cefsulodin: A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.Cephamycins: Naturally occurring family of beta-lactam cephalosporin-type antibiotics having a 7-methoxy group and possessing marked resistance to the action of beta-lactamases from gram-positive and gram-negative organisms.Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.Cephalosporins: A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid.Oxygen Compounds: Inorganic compounds that contain oxygen as an integral part of the molecule.Molecular Weight: The sum of the weight of all the atoms in a molecule.Fermentation: Anaerobic degradation of GLUCOSE or other organic nutrients to gain energy in the form of ATP. End products vary depending on organisms, substrates, and enzymatic pathways. Common fermentation products include ETHANOL and LACTIC ACID.Streptomyces: A genus of bacteria that form a nonfragmented aerial mycelium. Many species have been identified with some being pathogenic. This genus is responsible for producing a majority of the ANTI-BACTERIAL AGENTS of practical value.PiperidonesChemistry: A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.Amoxicillin-Potassium Clavulanate Combination: A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.Anti-Bacterial Agents: Substances that reduce the growth or reproduction of BACTERIA.Electron Transport Complex I: A flavoprotein and iron sulfur-containing oxidoreductase complex that catalyzes the conversion of UBIQUINONE to ubiquinol. In MITOCHONDRIA the complex also couples its reaction to the transport of PROTONS across the internal mitochondrial membrane. The NADH DEHYDROGENASE component of the complex can be isolated and is listed as EC 1.6.99.3.NADH Dehydrogenase: A flavoprotein and iron sulfur-containing oxidoreductase that catalyzes the oxidation of NADH to NAD. In eukaryotes the enzyme can be found as a component of mitochondrial electron transport complex I. Under experimental conditions the enzyme can use CYTOCHROME C GROUP as the reducing cofactor. The enzyme was formerly listed as EC 1.6.2.1.NADH, NADPH Oxidoreductases: A group of oxidoreductases that act on NADH or NADPH. In general, enzymes using NADH or NADPH to reduce a substrate are classified according to the reverse reaction, in which NAD+ or NADP+ is formally regarded as an acceptor. This subclass includes only those enzymes in which some other redox carrier is the acceptor. (Enzyme Nomenclature, 1992, p100) EC 1.6.Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.Operon: In bacteria, a group of metabolically related genes, with a common promoter, whose transcription into a single polycistronic MESSENGER RNA is under the control of an OPERATOR REGION.Gene Expression Regulation, Bacterial: Any of the processes by which cytoplasmic or intercellular factors influence the differential control of gene action in bacteria.Internet: A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.Developing Countries: Countries in the process of change with economic growth, that is, an increase in production, per capita consumption, and income. The process of economic growth involves better utilization of natural and human resources, which results in a change in the social, political, and economic structures.Software: Sequential operating programs and data which instruct the functioning of a digital computer.Medication Errors: Errors in prescribing, dispensing, or administering medication with the result that the patient fails to receive the correct drug or the indicated proper drug dosage.Biological Science Disciplines: All of the divisions of the natural sciences dealing with the various aspects of the phenomena of life and vital processes. The concept includes anatomy and physiology, biochemistry and biophysics, and the biology of animals, plants, and microorganisms. It should be differentiated from BIOLOGY, one of its subdivisions, concerned specifically with the origin and life processes of living organisms.User-Computer Interface: The portion of an interactive computer program that issues messages to and receives commands from a user.Algorithms: A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task.Computational Biology: A field of biology concerned with the development of techniques for the collection and manipulation of biological data, and the use of such data to make biological discoveries or predictions. This field encompasses all computational methods and theories for solving biological problems including manipulation of models and datasets.ArchivesMedical Illustration: The field which deals with illustrative clarification of biomedical concepts, as in the use of diagrams and drawings. The illustration may be produced by hand, photography, computer, or other electronic or mechanical methods.Information Storage and Retrieval: Organized activities related to the storage, location, search, and retrieval of information.Systems Integration: The procedures involved in combining separately developed modules, components, or subsystems so that they work together as a complete system. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)Cholera Vaccines: Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.Cholera: An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Physician-Patient Relations: The interactions between physician and patient.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Cholera Toxin: An ENTEROTOXIN from VIBRIO CHOLERAE. It consists of two major protomers, the heavy (H) or A subunit and the B protomer which consists of 5 light (L) or B subunits. The catalytic A subunit is proteolytically cleaved into fragments A1 and A2. The A1 fragment is a MONO(ADP-RIBOSE) TRANSFERASE. The B protomer binds cholera toxin to intestinal epithelial cells, and facilitates the uptake of the A1 fragment. The A1 catalyzed transfer of ADP-RIBOSE to the alpha subunits of heterotrimeric G PROTEINS activates the production of CYCLIC AMP. Increased levels of cyclic AMP are thought to modulate release of fluid and electrolytes from intestinal crypt cells.Phytotherapy: Use of plants or herbs to treat diseases or to alleviate pain.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Drugs, Chinese Herbal: Chinese herbal or plant extracts which are used as drugs to treat diseases or promote general well-being. The concept does not include synthesized compounds manufactured in China.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.BoliviaEcuadorBiotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.Moraceae: The mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.BrazilCaliforniaGenomics: The systematic study of the complete DNA sequences (GENOME) of organisms.Databases, Genetic: Databases devoted to knowledge about specific genes and gene products.Pseudomonas Infections: Infections with bacteria of the genus PSEUDOMONAS.Pseudomonas aeruginosa: A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection.Microbial Sensitivity Tests: Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.Bacteria: One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive.Pseudomonas: A genus of gram-negative, aerobic, rod-shaped bacteria widely distributed in nature. Some species are pathogenic for humans, animals, and plants.

Levels of cefmenoxime in sera and peritoneal tissues of patients undergoing gastrointestinal surgery. (1/55)

It is not known whether a prophylactic antibiotic administered prior to surgery reaches adequate levels in the peritoneum, where peritonitis may take place. This study determined levels of cefmenoxime in sera and peritoneal tissues of patients undergoing gastrointestinal surgery. Fifteen patients who underwent elective gastrointestinal surgery received an intravenous drip infusion of cefmenoxime (2 g) over 1 h prior to surgery. In patients who underwent gastrectomy, the level of cefmenoxime in serum was 130.8 +/- 6.9 micrograms/ml at laparatomy and decreased to 5.0 +/- 0.7 micrograms/ml at 4 h. Levels in parietal peritoneal and omental tissues at laparotomy were 35.3 +/- 5.2 and 19.2 +/- 3.5 micrograms, respectively, and decreased time dependently. In patients who underwent cholecystectomy, the level of cefmenoxime in serum was 137.9 +/- 7.3 micrograms/ml at laparotomy and decreased to 5.0 +/- 1.2 micrograms/ml at 4 h. Levels in parietal peritoneal and omental tissues were 31.0 +/- 8.4 and 13.7 +/- 3.3 micrograms/g, respectively, and decreased time dependently. The level of cefmenoxime in serum correlated with the levels of cefmenoxime in parietal peritoneum (r = 0.64, P less than 0.01) and in omentum (r = 0.47, P less than 0.02). In patients with appendicitis who received a bolus injection of 2 g of cefmenoxime, the level of drug in inflammatory omental tissue correlated with the level in serum. The levels in peritoneal tissue during surgery lasting up to 2 h were significantly greater than in MIC of cefmenoxime against almost all bacteria reported. A preoperative single dose of 2 g of cefmenoxime probably is effective as a prophylactic for intraoperative contamination.  (+info)

Synergistic effects of romurtide and cefmenoxime against experimental Klebsiella pneumonia in mice. (2/55)

We investigated the synergistic effects of romurtide (MDP-Lys [L18]) and cefmenoxime (CMX) in the treatment of experimental Klebsiella pneumonia in mice. Mice were infected with 1 x 10(4) CFU of Klebsiella pneumoniae by inhalation of aerosol bacterial suspension. About 90% of untreated animals died within a week; however, the mortality rate of animals treated with CMX alone at a dose of 40 mg/kg/day was 60% at 7 days after the infection. When one or two doses of L18 were administered before or after the infection concomitantly with CMX, a remarkable improvement in the survival rate was observed. There was no significant improvement in the survival rate of animals treated with L18 alone before or after infection. Histopathological sections of the lungs of mice treated with CMX and L18 showed slower progression of infection than those of mice treated with CMX alone. Significant differences were also found in quantitative cultures of viable bacteria in the lungs 1 to 4 days after the infection. Although viable bacterial counts in the lungs of the control and CMX-treated groups showed a rapid increase 24 to 48 h after the infection, they remained lower than the initial counts (x 10(4)) in the lungs of mice treated with combination regimens. From these results, it can be concluded that L18 is a useful biological response modifier in the treatment of acute pulmonary bacterial infections.  (+info)

Studies on condensed-heterocyclic azolium cephalosporins. III. Synthesis and antibacterial activity of 7 beta-[2-(2-amino-5-substituted-thiazol-4-yl)-2 (Z)-alkoxyiminoacetamido]-3-(condensed-heterocyclic azolium)methyl-3-cephem-4- carboxylates. (3/55)

As a part of our research on the synthesis of cephalosporins bearing condensed-heterocyclic azolium groups at the 3 position in the cephalosporin nucleus, we describe herein the synthesis of 7 beta-[2-(2-amino-5-halogeno-, methylthio-, methylsulfinyl-, methylsulfonyl- and sulfothiazol-4-yl)-2(Z)-alkoxyiminoacetamido] cephalosporins and their antibacterial activity. Among the compounds prepared, 7 beta-[2-(2-amino-5-chlorothiazol-4-yl)-2(Z)- methoxyiminoacetamido]-3-(imidazo[1,5-a]-pyridinium-1-yl)methyl-3-cephem -4-carboxylate (14) showed good antibacterial activity against both Staphylococcus aureus including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, whereas the antibacterial activity against other Gram-negative bacteria was a slightly lower than that of 7 beta-[2-(2-aminothiazol-4-yl)-2(Z)-methoxyiminoacetamido]-3-(im ida zo [1,2-a]pyridinium (I-1) and imidazo[1,5-a]pyridinium (I-4)-1-yl)methyl-3-cephem-4-carboxylates.  (+info)

Application of mathematical model to multiple-dose experimental chemotherapy for fatal murine pneumonia. (4/55)

Two beta-lactam antibiotics, cefazolin and cefmenoxime, were administered for 7 days to mice with pneumonia caused by Klebsiella pneumoniae by using dosage regimens that would simulate multiple dosing in usual clinical treatments at dosing intervals of 8 or 12 h. Viable numbers of the bacteria in the lungs were measured at 12- or 24-h intervals. The mathematical model established in a previous single-dose study was applied in this study to explain the time courses of the changes in bacterial count over 7 days. However, because the error in viable count measurements was larger than that in the previous study, the time course of the changes in mean viable count was not regular and the viable count reduction rate changed during multiple dosing, and therefore it was difficult to explain the time course by repeated application of the mathematical model described previously. This study suggests that the changes in pharmacokinetic and pharmacodynamic parameters during multiple dosing need to be considered.  (+info)

Paradoxical activity of beta-lactam antibiotics against Proteus vulgaris in experimental infection in mice. (5/55)

In previous papers (Y. Ikeda and T. Nishino, Antimicrob. Agents Chemother. 32:1073-1077, 1988; Y. Ikeda, T. Nishino, and T. Tanino, Antimicrob. Agents Chemother. 31:865-869, 1987), we reported that many of the 7-aminothiazolyl cephalosporins, such as cefmenoxime, showed paradoxically reduced activity against Proteus vulgaris at higher concentrations, whereas these paradoxical effects were not observed for other types of cephalosporins, such as cefbuperazone and cefoperazone. In this study, we compare the therapeutic effect of cefmenoxime with that of cefbuperazone and explore the in vivo paradoxical effect of cefmenoxime by using an experimental infection model in mice. In an intraperitoneal infection with P. vulgaris 11, the survival rate with cefmenoxime was increased to 43% at 3.13 mg/kg but was lower at higher doses. On the other hand, cefbuperazone did not show such a paradoxical therapeutic effect. In mice infected with P. vulgaris 11, cefmenoxime levels in both serum and peritoneal washings were rapidly reduced and beta-lactamase activities in the peritoneal cavity were increased at higher cefmenoxime doses. These findings suggested that high levels of cefmenoxime at the infection site induced increased production of beta-lactamase, which then rapidly inactivated the antibiotic. We conclude that the paradoxical therapeutic effect of cefmenoxime against P. vulgaris occurs by the same mechanisms as the in vitro effect and that the high beta-lactamase inducibility and low beta-lactamase stability may account for the paradoxical therapeutic effect of cefmenoxime against P. vulgaris.  (+info)

Application of mathematical model to experimental chemotherapy of fatal murine pneumonia. (6/55)

Two beta-lactam antibiotics, cefazolin and cefmenoxime, were administered in an experimental model of murine pneumonia caused by Klebsiella pneumoniae in a way which enabled us to approximate the serum antibiotic concentration time course in humans. Bacterial counts during the experiments were subjected to nonlinear least-squares analyses by using a mathematical model that explained the bacterial killing by the antibiotic concentration time course and other factors associated with antimicrobial potency and bacterial growth. Cefazolin gave a killing curve that changed synchronously with the drug levels in serum; in contrast, cefmenoxime gave a curve that was prolonged as compared with the change in the drug levels in serum. Multiple correlation coefficients were about 0.9, and the model worked well for bacterial count data. Parameters relating to antimicrobial potency of the drugs, bacterial growth rate, and drug distribution into the tissue were estimated numerically.  (+info)

In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines. (7/55)

To determine the cytotoxicity of antibiotic eyedrops to ocular surface cells using a semi-quantitative method, a range of commercially available antibiotic eyedrops were assessed by using three corneal cell lines and one conjunctival cell line. All antibiotic solutions were free of benzalkonium chloride. Cell viability was determined by the MTT assay and neutral red assay following the exposure of cells to the undiluted, 2- and 10-fold diluted drugs for 10, 30, and 60 min. Toxicity was compared using % cell viability score (%CVS) . The tested eyedrops and values of %CVS50 and %CVS40/80 were Bestron((R)) (cefmenoxime, 100, 94) , Panimycin((R)) (dibekacin, 86, 58) , Noflo((R)) (norfloxacin, 90, 50) , Cravit((R)) (levofloxacin, 86, 46) , Tosfulo((R)) (tosufloxacin, 57, -3) , and Vigamox((R)) (moxifloxacin, 57, -6) . Cell viability markedly increased after dilution. For instance, cell viability assayed by MTT was > 80% for all the measurements in antibiotics diluted 10-fold, and the rate of the measurements showing > 80% cell viability decreased to 43% (31 out of 72 measurements) in the solutions diluted 2-fold. Of the drugs tested, Bestron((R)) containing cefmenoxime showed the weakest toxicity. Vigamox((R)) containing moxifloxacin and Tosuflo((R)) containing tosufloxacin were more toxic when compared with the other antibiotics. CVS was useful for the comparison of the cytotoxicity of the drugs.  (+info)

Antimicrobial activity and stability to beta-lactamase of BMY-28271, a new oral cephalosporin ester. (8/55)

BMY-28271, the acetoxyethyl ester of BMY-28232, 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3(Z) -propen-1-yl-3- cephem-4-carboxylic acid, is a new oral cephalosporin. BMY-28232 has a widely expanded spectrum with high activity against gram-positive and gram-negative bacteria. BMY-28232 is far more active than cefixime or cefteram against Staphylococcus aureus and Staphylococcus epidermidis. Against gram-negative bacteria, the activity of BMY-28232 was comparable to or somewhat weaker than that of cefixime or cefteram. BMY-28232 was a poor substrate for various beta-lactamases. Orally administered BMY-28271 had a good therapeutic effect on systemic infections with S. aureus and some gram-negative bacteria in mice. Oral BMY-28271 was efficacious against S. aureus Smith infection: the efficacy of BMY-28271 was 80 to 90 times higher than that of cefixime or cefteram.  (+info)

*Cefmenoxime

... is a third-generation cephalosporin antibiotic. DDB 30892 Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, ... Duncker G, Reich U, Krausse R (1994). "Cefmenoxime in corneal organ culture". Ophthalmologica. 208 (5): 262-6. doi:10.1159/ ... Paladino J, Fell R (1994). "Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial ... Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T (1995). "Antibacterial activities of cefmenoxime against recent fresh clinical ...

*Cephalosporin

These include latamoxef (moxalactam), cefmenoxime, cefoperazone, cefamandole, cefmetazole, and cefotetan. This is thought to be ...

*TAP Pharmaceuticals

The first products TAP file new drug applications for, were two cephalosporins, cefmenoxime (Cefmax) and cefsulodin (Cefonomil ...

*List of MeSH codes (D02)

... cefmenoxime MeSH D02.065.589.099.249.190.190.135 --- cefotiam MeSH D02.065.589.099.249.190.190.145 --- ceftizoxime MeSH D02.065 ...

*Disulfiram-like drug

... cefmenoxime, cefmetazole, cefonicid, cefoperazone, cefotetan, ceftriaxone, cefuroxime, and latamoxef (moxalactam); thought to ...

*Sodium salts

Example of such sodium salts are (selection): Bispyribac, bithionol, bosentan, brequinar, bromfenac, Cefmenoxime, ceftiofur, ...

*List of drugs: Cb-Ce

Cefmax cefmenoxime (INN) cefmepidium chloride (INN) cefmetazole (INN) cefminox (INN) Cefobid cefodizime (INN) cefonicid (INN) ...

*ATC code J01

J01DC14 Flomoxef J01DD01 Cefotaxime J01DD02 Ceftazidime J01DD03 Cefsulodin J01DD04 Ceftriaxone J01DD05 Cefmenoxime J01DD06 ...

*Timeline of antibiotics

... cefmenoxime 1983 - ceftazidime 1983 - ceftizoxime 1983 - norfloxacin 1984 - cefonicid 1984 - cefotetan 1984 - temocillin 1985 ...
[Study of clinical bacteriological efficacy in a cefmenoxime ototopical solution].: One percent cefmenoxime (CMX) ototopical solution was administered to 302 pa
Cefmenoxime is a medicine available in a number of countries worldwide. A list of US medications equivalent to Cefmenoxime is available on the Drugs.com website.
Product Number , 78097775. CAS Number , 75738-58-8. EC , Molecular Formula , C16H18ClN9O5S3. Molecular Weight , 548.02. Storage Temp , Harmonized Tariff code , 29419000. Signal Word , ...
1LSP: Structure of a bulgecin-inhibited g-type lysozyme from the egg white of the Australian black swan. A comparison of the binding of bulgecin to three muramidases.
Synthesis and structure-activity relationships of 7.BETA.-[2-(2-aminothiazol-4-yl)acetamido]-cephalosporin derivatives. III. Synthesis and antibacterial activity of 7.BETA.-[2-amino-2-(2-aminothiazol-4-yl)acetamido]cephalosporins.:III. SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF 7β-[2-AMINO- 2-(2-A MINOTHIAZOL-4-YL)ACETAMIDO]CEPHALOSPORINS (1980 ...
A new broad-spectrum generation wormer for pigs that can be administered through drinking water has been launched at the Pig and Poultry Fair 2012.
We,China 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 Suppliers and China 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 Manufacturers, provide 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 product and the products related with China 7-AMINO-3-CHLOROMETHYL-3-CEPHEM-4-CARBOXYLIC ACID P-METHOXYBENZYL ESTER, HYDROCHLORIDE 113479-65-5;115369-44-3 - Otsuka Chemical
Doctors give trusted answers on uses, effects, side-effects, and cautions: Dr. Khairullah on nitrofurantoin side effects: Outside of allergic reactions, which are not unique to cefdinir, none of the cephalosporins have side-effects which are very significant. They include cases of gastrointestinal discomfort with nausea, vomiting and diarrhea and rash as occasional occurrences. Sold as omnicef, it is one of several oral cephalosporins.
InChI=1S/C14H15N5O5S2/c1-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24-2)6-4-26-14(15)16-6/h4,8,12H,3H2,1-2H3,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/ ...
an oral cephalosporin (trade names Keflex and Keflin and Keftab) commonly prescribe for mild to moderately severe infections of the skin or ears or throat or lungs or urinary tract. ...

Cefmenoxime - Drugs.comCefmenoxime - Drugs.com

A list of US medications equivalent to Cefmenoxime is available on the Drugs.com website. ... Cefmenoxime is a medicine available in a number of countries worldwide. ...
more infohttps://www.drugs.com/international/cefmenoxime.html

Cefmenoxime | The Merck Index OnlineCefmenoxime | The Merck Index Online

Cefmenoxime , Monograph containing literature references, physical and biological properties and relevant information ...
more infohttps://www.rsc.org/Merck-Index/monograph/m3196?q=unauthorize

Cefmenoxime - WikipediaCefmenoxime - Wikipedia

Cefmenoxime is a third-generation cephalosporin antibiotic. DDB 30892 Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, ... Duncker G, Reich U, Krausse R (1994). "Cefmenoxime in corneal organ culture". Ophthalmologica. 208 (5): 262-6. doi:10.1159/ ... Paladino J, Fell R (1994). "Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial ... Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T (1995). "Antibacterial activities of cefmenoxime against recent fresh clinical ...
more infohttps://en.wikipedia.org/wiki/Cefmenoxime

Cefmenoxime hydrochloride | PhionCefmenoxime hydrochloride | Phion

Product Number , 78097775. CAS Number , 75738-58-8. EC , Molecular Formula , C16H18ClN9O5S3. Molecular Weight , 548.02. Storage Temp , Harmonized Tariff code , 29419000. Signal Word , ...
more infohttp://phionchemicals.com/product/cefmenoxime-hydrochloride

Carboplatin, Cefmenoxime, Zidovudine

 | DIAL.pr - BOREALCarboplatin, Cefmenoxime, Zidovudine | DIAL.pr - BOREAL

Harvengt, C.. Carboplatin, Cefmenoxime, Zidovudine. In: Acta Clinica Belgica (Multilingual Edition), Vol. 42, no. 6, p. 468-472 ...
more infohttps://dial.uclouvain.be/pr/boreal/object/boreal:53318

Study of clinical bacteriological efficacy in a cefmenoxime o...Study of clinical bacteriological efficacy in a cefmenoxime o...

One percent cefmenoxime (CMX) ototopical solution was administered to 302 pa ... Study of clinical bacteriological efficacy in a cefmenoxime ototopical solution].: ... Study of clinical bacteriological efficacy in a cefmenoxime ototopical solution].. Authors * Deguchi, K ... One percent cefmenoxime (CMX) ototopical solution was administered to 302 patients with purulent otitis media and acute diffuse ...
more infohttps://www.mysciencework.com/publication/show/study-clinical-bacteriological-efficacy-cefmenoxime-ototopical-solution-6c3bf8ec

En Nuo Ni - Drugs.comEn Nuo Ni - Drugs.com

Cefmenoxime. Cefmenoxime hydrochloride (a derivative of Cefmenoxime) is reported as an ingredient of En Nuo Ni in the following ...
more infohttps://www.drugs.com/international/en-nuo-ni.html

Antifection<...Antifection<...

Cefmenoxime Hydrochloride is a cephalosporin antibiotic that is administered intravenously or intramuscularly. Learn More ... Cefmenoxime hydrochloride Catalog No. A16156. Quick View .category-products .products-list .btn-quickcart { background: white; ...
more infohttps://www.adooq.com/antifection.html

Cholera Vaccine (Oral Route) Description and Brand Names - Mayo ClinicCholera Vaccine (Oral Route) Description and Brand Names - Mayo Clinic

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this vaccine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.. Receiving this vaccine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.. ...
more infohttps://www.mayoclinic.org/drugs-supplements/cholera-vaccine-injection-route/description/drg-20062780?p=1

Perkins RL[au] - PubMed - NCBIPerkins RL[au] - PubMed - NCBI

Cefmenoxime: clinical evaluation.. Baker RL, Perkins RL.. Am J Med. 1984 Dec 21;77(6A):53-9. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Perkins+RL%5Bau%5D&dispmax=50

Penicillin-binding protein 1A - DrugBankPenicillin-binding protein 1A - DrugBank

Cefmenoxime. approved. yes. inhibitor. Details. DB00301. Flucloxacillin. approved, investigational. yes. inhibitor. Details. ...
more infohttps://www.drugbank.ca/bio_entities/BE0000576

Antiinfectives | SCBT - Santa Cruz BiotechnologyAntiinfectives | SCBT - Santa Cruz Biotechnology

Cefmenoxime hydrochloride An antibacterial 75738-58-8. sc-278818 25 mg. $196.00 0 ...
more infohttps://www.scbt.com/zh/browse/antiinfectives/_/N-1uw5a5x

WHOCC - ATC/DDD IndexWHOCC - ATC/DDD Index

cefmenoxime 2 g P J01DD06 latamoxef 4 g P J01DD07 ceftizoxime 4 g P ...
more infohttps://www.whocc.no/atc_ddd_index/?code=J01DD&showdescription=yes

Cefsulodin
     Summary Report | CureHunterCefsulodin Summary Report | CureHunter

Cefmenoxime (Cefmax) 7. cefpiramide 8. Gentamicins (Gentamicin) 9. Rifampin (Rifampicin) 10. Inulin ...
more infohttp://www.curehunter.com/public/keywordSummaryD002441-Cefsulodin.do

CA2704853C - Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties 
        - Google...CA2704853C - Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties - Google...

Cefepime Hydrochloride; Cefetecol; Cefixime; Cefmenoxime Hydrochloride; Cefmetazole; Cefmetazole Sodium; Cefonicid Monosodium; ...
more infohttps://patents.google.com/patent/CA2704853C/en

WikiGenes - Microbial Sensitivity TestsWikiGenes - Microbial Sensitivity Tests

Cefmenoxime: in vitro activity. Stamm, J.M. Am. J. Med. (1984) [Pubmed] ... The minimum inhibitory concentration (MIC) of cefmenoxime required to inhibit at least 90 percent of strains tested (MIC90) ...
more infohttps://www.wikigenes.org/e/mesh/e/543.html

Cephalosporin Antibiotics: Generations, Uses, Side EffectsCephalosporin Antibiotics: Generations, Uses, Side Effects

Hypoprothrombinemia (deficiency of prothrombin in the blood) is common with cefoperazone, cefamandole, cefotetan, cefmenoxime11 ...
more infohttps://www.emedexpert.com/compare/cephalosporins.shtml

CiNii Articles - OKAMOTO TADAATSUCiNii Articles - OKAMOTO TADAATSU

An Investigation on Education for International Understanding : To Examine"Test of International Understanding(II)"compiled by the Sub-Committee on Experimental Activities of Educaational Understandings with the Japanese National Commission for Unesco in 1954 (1986 ...
more infohttps://ci.nii.ac.jp/author?q=OKAMOTO+TADAATSU

Antibiotic - Unionpedia, the concept mapAntibiotic - Unionpedia, the concept map

New!!: Antibiotic and Cefmenoxime · See more ». Cefoperazone. Cefoperazone is a third-generation cephalosporin antibiotic, ... Cefmenoxime. Cefmenoxime is a third-generation cephalosporin antibiotic.. ... Cefmenoxime, Cefoperazone, Ceftaroline fosamil, Ceftazidime, Ceftolozane, Cellulitis, Centers for Disease Control and ...
more infohttps://en.unionpedia.org/Antibiotic

CiNii Articles - KUBOTA SunaoCiNii Articles - KUBOTA Sunao

CEFMENOXIME CONCENTRATIONS IN HUMAN BLOOD, BILE AND GALLBLADDER IN ADMINISTRATION BEFORE SURGERY (1985) ...
more infohttps://ci.nii.ac.jp/author?q=KUBOTA+Sunao

API-Audits und API-Auditberichte: Liste der Wirkstoffe | DiapharmAPI-Audits und API-Auditberichte: Liste der Wirkstoffe | Diapharm

Aktuelle API Auditberichte • GMP-Audits der Herstelung pharmazeutischer Ausgangs- und Wirkstoffe nach ICH Q7 / EU GMP Guide Part II • Diapharm
more infohttps://www.diapharm.com/arzneimittel/api-audits/api-auditberichte/

C-化学物质数据库C-化学物质数据库

Cefmenoxime(Antibacterial.). *Cefmetazole(Antibacterial.). *Cefminox(Antibacterial.). *Cefodizime(Antibacterial.). *Cefonicid( ...
more infohttps://www.drugfuture.com/chemdata-c.html
  • One percent cefmenoxime (CMX) ototopical solution was administered to 302 patients with purulent otitis media and acute diffuse external otitis in open study fashion, and to 216 patients with purulent otitis media in double blind condition. (mysciencework.com)
  • 3-4s) is a vasovagal reaction with cefmenoxime, cefotetan, cefopera- zone, cefamandole, and moxalactam after the high-calorie meal. (wisc.edu)